Performance of mid-term in 2001 Progress status of medium term management plan "WIT2000"

Technology and intelligence oriented company that turns wisdom into business Nagase & Co., Ltd.

Consolidated performance

(Unit; hundred million yen)

	01/09	00/09	Ratio over previous year (%)	Consolidated versus independent (time)
Sales	2,576	2,862	90.0	1.20
Gross Profit	240	284	84.8	1.83
Operating Income	7	41	19.0	
Ordinary Income	24	52	45.6	2.45
Intermediate(current term) net profit before tax	33	59	55.3	2.84
Intermediate(current term) net profit	16	29	56.7	1.42
Intermediate(current term) net profit per share	12.19 yen	21.21 yen		
ROE	2.2 %	4.1 %		

Consolidated is 28 and partnership is 8.

(Note; Change in the consolidated)

Nagase Biochemicals, Ltd., Nagase Chemicals Ltd., Teikoku Chemical Industries Co., Ltd.

 \rightarrow combined to Nagase ChemteX Ltd.


Nagase Europe Ltd. \rightarrow liquidated

Sales and Gross Profit by each segment

(Unit; hundred million yen)

	Sales			G	Ratio of Gross Profit to Sales		
	01/09	00/09	% change	01/09	00/09	% change	01/09
Chemicals	1,134	1,205	94.0%	91	98	92.9%	8.1%
Plastics	941	1,039	90.6%	65	87	74.7%	7.0%
Electronics	439	550	79.8%	68	74	91.9%	15.5%
Health Care	60	66	90.8%	15	23	65.2%	25.7%
Total	2,576	2,862	90.0%	240	284	84.5%	9.3%

Products sales composition by each segment



Graph of stock price fluctuation: Left(00/09) Right(01/09) (); comparison of the current vs. the previous year



Major increase and decrease in B/S

(Unit; hundred million yen)

(Assets)	01/09	01/03	Increase & decrease	(Liabilities & Shareholder's equity)	01/09	01/03	Increase & decrease
Cash and deposits with banks	224	214	10	Trade notes and accounts payable	1,177	1,343	riangle 165
Trade notes and accounts receivable	1,661	1,844	riangle 182	Short term loans payable	99	140	riangle 40
Inventories	287	341	riangle 54	Commercial paper	10		10
Other current assets	58	61	$\triangle 3$	Other current liabilities	146	198	riangle 51
Tangible fixed assets	236	247	riangle 10	Bond	70	70	0
Investments in securities	665	763	riangle 97	Long term loans payable	27	28	$\bigtriangleup 1$
Other fixed assets	59	64	riangle 5	Other fixed liabilities	139	183	$\triangle 44$
				(debt with interest)	(206)	(238)	(⊿31)
				Other fixed liabilities	38	38	0
				Shareholder's equity	1,484	1,534	riangle 50
				(Ratio of shareholders' equity)	(46.5%)	(43.4%)	(3.1.%)
Total Assets	3,193	3,537	riangle 344	Total liabilities, minority interests and shareholders' equity	3,193	3,537	△ 344



(Unit; a million yen)

	01/09	00/09	Increase & decrease
Cash flows from operating activities	5,397	8,263	riangle 2,866
Cash flows from investing activities	riangle 505	riangle 2,479	1,974
Cash flows from financing activities	△ 4,741	\triangle 5,622	881
Effect of exchange rate changes on cash and cash equivalents	1,013	190	823
Net increase(decrease) in cash and cash equivalents	1,164	352	812
Effect of exchange rate changes on cash and cash equivalents	18,465	21,015	riangle 2,550
Increase in cash equivalents arising merger of unconsolidated subsidiaries	$\triangle 258$	680	△ 938
Cash and cash equivalents at end of the year	19,371	22,049	riangle 2,678

Performance of major consolidated

(Unit; a million y							
Sales	Ratio over previous year	Operating Income	Ratio over previous year	Intermediate net profit	Ratio over previous year		
9,734	80%	193	33%	281	68%		
8,005	104%	97	68%	73	50%		
4,764	84%	11	20%	7	21%		
1,213	114%	72	76%	36	68%		
8,263	95%	76	128%	28	3620%		
1,534	82%	155	121%	100	137%		
3,423	91%	$\triangle 226$	70%	753	—		
10,547	113%	345	75%	317	80%		
15,417	86%	204	43%	229	79%		
5,809	126%	221	101%	164	94%		
6,109	80%	92	148%	77	104%		
3,159	180%	53	73%	47	54%		
3,804	100%	62	44%	13	16%		
	9,734 8,005 4,764 1,213 8,263 1,534 3,423 10,547 15,417 5,809 6,109 3,159	Datesprevious vear9,73480%8,005104%4,76484%1,213114%8,26395%1,53482%3,42391%10,547113%15,41786%5,809126%6,10980%3,159180%	Datesprevious yearIncome $9,734$ 80% 193 $8,005$ 104% 97 $4,764$ 84% 11 $1,213$ 114% 72 $8,263$ 95% 76 $1,534$ 82% 155 $3,423$ 91% $\triangle 226$ $10,547$ 113% 345 $15,417$ 86% 204 $5,809$ 126% 221 $6,109$ 80% 92 $3,159$ 180% 53	SafesIntro otclIncomeIncome $9,734$ 80% 193 33% $8,005$ 104% 97 68% $4,764$ 84% 11 20% $1,213$ 114% 72 76% $8,263$ 95% 76 128% $1,534$ 82% 155 121% $3,423$ 91% $\triangle 226$ 70% $10,547$ 113% 345 75% $15,417$ 86% 204 43% $5,809$ 126% 221 101% $6,109$ 80% 92 148% $3,159$ 180% 53 73%	SalesRatio over previous yearOperating IncomeRatio over previous yearIntermediate net profit9,73480%19333%2818,005104%97768%734,76484%11120%771,213114%72276%3668,26395%766128%2881,53482%155121%1003,42391%△ 22670%75310,547113%34575%31715,41786%20443%2295,809126%221101%1646,10980%92148%773,159180%5373%47		

(Notes;

NagaseChemteX merged NagaseBiochemicals, NagaseChemical and TeikokuChemicalIndustries at April 1,2001. The ratio over previous year about NCX is to compare with the simple sum that all merged companies.

Status of Stock Buy-back

	Total number of shares (unit; thousand stocks)	Aggregate cost (unit; a million yen)	The way to deal
1998	5, 349	2,355	Buy back
1999	4,542	2,117	Buy back
2000	2,600	1,256	Buy back
2001 (First half of the year)	529	266	Buy back
2001 (Second half of the year)	5, 166	2, 675	Possession
Total	18,186	8, 672	

Expected business performance(estimated)

(Unit; hundred million yen)

									J
				2001		2000		Against previous	
			(fo	recast)	(performance)		year	(%)	
	Sales	ules		4,780	4	5,593		85.5	
	Gross Pr	oss Profit		468		551		84.9	
	Selling general and administrative expenses			455	473			96.0	
	Operatin	ng Income		13		77		16.8	
	Non operation expenses	ng income and		29		25		114.6	
	Gross Profit			42	102			40.8	
	Net Income			17		49		34.4]
	Sal		Salas	as		bross Pro	ofit		
		2001	2000	Against previous	2001	200)()	Against pre	vious
		(forecast)	(performance)	year (%)	(forecast)	(perform	nance)	year	(%)
Ch	emicals	2,130	2,378	89.5	171	1	98	86.	.1
Pla	astics	1,725	2,054	84.0	138	1	71	80.	.4
Ele	ectronics	800	1,033	77.4	126	1	48	84	.8
He	althCare	125	126	98.8	33		32	101	.4
	Total	4,780	5,593	85.5	468	5	51	84.	.9

Progress status of medium term management plan "WIT2000"

Creation of new business

Outline of the plan

Intensive investment in strategic field (Electronics,HealthCare)
Emphasis on consolidated group management
Focus on B/S , CF

(unit; hundred million yen) Sales	2000 (performance) 5,593		2001 forecast) ,780	(6,090)	2002 (under review) (6,400)
Net Income	49	(52)	17	(68)	(83)
ROA (%)	1.5	(1.5)	0.5	(2.1)	(2.5)
ROE (%)	3.4	(3.5)	1.1	(4.9)	(5.8)
N-ROE (%)	5.0	(6.0)	2.5	(6.2)	(7.0)

10

The dramatic changes in management environment



Management streamlining

1. The cost expenses cutback

Cut the directors remuneration at the maximum of 20%

Cut the year-end bonus of administrative positions at the maximum of 20%

Cut the selling, general and administrative expenses by efficiency and rationalization of the business

> The selling, general and administrative expenses in2001; cut 1.7 billion yen (Against previous non consolidated year)

2. The reduction of employment

- Enforcement of the early retirement system (the second half of 2001)
- Enforcement of cut 100 employment in two years from now. (include the natural decrease about 10% of the all staffs)

3. Withdrawal from the business of non-core, low growth and low profits

Nagase Medical Co.,

Focus on the contract manufacture, transfer the sales section

The temporary employment business

withdrawal

Nagase Kisho Electronics Co.,(TV assembly company) liquidation

4. Cash flow efficiently in the group

Plan to introduce the cash management system


- The period : the trial introduction February in 2002 the full introduction on and after May in 2002
- (2) The number of target company : $20 \sim 30$ domestic subsidiaries
- 3 Cut down the consolidated debt (Loans Payable, CP and Bond)

(the total consolidated debt is 5.5 billion as of end Sep, 2001)



Reinforcement and expansion top share business

Speed up creation of new business



Reinforcement and expansion of top share business

Sales : about 150 billion yen

Investment to the related business : 10 billion yen (since 1999)

Making use of our R&D and

manufacturing function for dealing product

Color Former Investment to capacity expansion

Chemical Management System Establish Nagase CMS technology co.

Standard system in the industry

Wireless communications modules Establish the factory in Gigatech Co.,

Photosensitive drum and film Surface defect inspection equipment

De facto standard by promoting the business

NCX special epoxy monomer

Promote the fusion between monomer and polymer technology NCX enzymes and bulk biocides

Research the chirotechnology and enzymes application in NCX and our R&D

Reinforcement and expansion the top share business

Providing of quality marketing and sales force

Liquid crystal material business

Chinese components business, Establish Nagase Finechem Singapore Precision abrasive materials business

Establish JV in Asia and china / Sell the our original merchandise **Dyestuffs and functional pigment business**

Reinforce china business aiming at No.1 in Asia / Enforce CRM (Customer relationship management) Coating,Ink material business

Investment / plan JV in overseas / improvement industry share Pharmaceuticals(intermediates) and contract business Establish NCX / Increase the equipment to compose pharmaceuticals / Investment

Speed up the creation of new business

Expand the new business that is connected directly with the market.

Overseas *Establish JV that is related with plastics for automobile industry(China) *****Promote the sales of wireless communications modules(Korean,China) *Establish the company that manufactures liquid ingredient for liquid crystal(Singapore) *Expand the business that assemble and produce the liquid crystal display materials(China) *Establish the company that manufactures the tray for electronic products(China) *Global development the semiconductor encapsulation **material**(LSE)(all over the world) *Investment the venture company that conducts research in immunotherapy(America)

Speed up the creation of new business

Expand the new business that is connected directly with the market.

Domestic

*Establish the plant for pharmaceutical intermediates synthesis in NCX *Network business in Hoei Sangyo Co.

***Business for medical facilities**

(electronic medical records, infectious disease control systems) *E-commerce business

(DVD, health food, Environments related software) *Pluswood(plastic compound building material containing more than 51% by weight of wooden material)

Business strategy for liquid crystal material in Asia(China) Korean Expand the liquid crystal business **Alliance with Korea Kumho Petrochemical Co.** China NC) manufacture **Expand the components** liquid medicine assembly business NCM manufacture device Taiwan Nagase Finechem Shingapore Co. manufacture liquid medicine *manufacture chemical to produce the liquid medicine Nagase Singapore(Pte)Ltd. *The fourth base after

Japan, Korean and Taiwan

Supply chemical and liquid crystal materials



The technology-information oriented company that turns wisdom into business



Nagase & Co., Ltd.

This information for presentation includes estimate based on premise, prospects and plan for future as of November 29, 2001. Depending on risks or unknown factors concerning world economy, competitive situation and exchange rate, there is a possibility of difference between actual performance and the above forecast